Research News & Funding Opportunities for Tulane Cancer Researchers - July 15, 2025 | |
From Connection to Collaboration: CancerConnect Builds Bridges to
Advance Cancer Research
| | Over 50 faculty members and trainees from Tulane Cancer Center and the Tulane School of Science & Engineering came together last week for CancerConnect, a networking event designed to spark conversations and support collaboration across the University's cancer-focused community. Attendees were challenged by Dr. Stefan Grant, Director of the Tulane Cancer Center, and Dr. Hridesh Rajan, Dean of the School of Science & Engineering, to make new connections at the event and to think boldly about how interdisciplinary partnerships can advance cancer research. Conversations centered around key themes -- including AI and data science, biomedical engineering, medicinal chemistry, and computational biology -- highlighting exciting opportunities for synergy across schools and disciplines. Thank you to all who joined us for this energizing event. We look forward to seeing the collaborations that grow from these connections and to building even more bridges at future CancerConnect gatherings. | | |
LCRC Trainee Travel Awards
DEADLINE: JULY 15, 2025
The Louisiana Cancer Research Center (LCRC) is offering travel awards designed to enhance the training experiences of undergraduate students, graduate students, and postdoctoral trainees in LCRC-affiliated laboratories.
This funding opportunity is designed to support travel to national meetings where awardees will present their research.
Eligibility Criteria:
- Undergraduate students (Junior or Senior), graduate students (2-5 years in the program), and postdoctoral trainees (within 3 years of receiving their PhD)
- The applicant’s Principal Investigator (PI) must be a member of the LCRC.
- The applicant must present either a poster or a platform presentation at a conference within the continental United States.
- Travel must commence no earlier than July 15, 2025, and conclude before December 31, 2025.
- Previous awardees from the last two funding periods are ineligible.
- Trainees from laboratories that received two LCRC travel awards in the last two funding periods are also ineligible
Applications can be submitted through the LCRC's Submittable portal, a new tool designed to enhance the submission experience, prevent processing issues, and streamline the review process.
Click HERE for instructions for setting up your Submittable account.
MORE INFORMATION
| | |
OPEN DEADLINE -
EARLIEST SUBMISSION JULY 19
The NIH Director’s New Innovator Award supports early stage investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. Applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research.
MORE INFORMATION
| | |
New! Cost caps for all FY25 PRMRP funding opportunities have been changed from direct costs to total costs (direct plus indirect costs).
Peer Reviewed Medical Research Program (PRMRP):
The maximum allowable funding for FY25 PRMRP funding opportunity is summarized below:
-
Technology/Therapeutic Development Award: $3.5M total costs (direct plus indirect costs)
To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671101
IMPORTANT: The updated program announcements have been posted to Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Updates to program announcements that were posted to the CDMRP website are pending and will be updated soon.
| | |
Request for Proposals - Clinical Updates and Strategies in the Treatment and Management of First-line BRAF V600E-mutant Metastatic Colorectal Cancer (mCRC) and Metastatic Non-Small Cell Lung Cancer (mNSCLC)
DEADLINE - JULY 23
Projects considered for Pfizer support will:
- Increase understanding and awareness of the latest clinical data updates and guideline recommendations relevant to the first line treatment of patients with BRAF V600E-mutant mCRC and mNSCLC.
- Optimize BRAF inhibitor-based treatment for BRAF V600E-mutant mCRC and mNSCLC through proper management of adverse events through dose modifications and supportive care.
- Increase awareness of BRAF V600E biomarker testing and first-line treatment options in mCRC and mNSCLC in the community setting.
- Maximize therapy management strategies of BRAF inhibitor combination therapies through collaboration between experts in academic centers and community oncologists.
If you're interested in applying, please contact Tony Enterante, Ed.D, MBA, senior development officer for corporate, foundation and research relations, at aenteranteiii@tulane.edu.
MORE INFORMATION
| | |
The Mark Foundation for Cancer Research Endeavor Award
EXPRESSION OF INTEREST DEADLINE - JULY 23
LETTER OF INTENT DUE - SEPTEMBER 3
AWARD AMOUNT - $3,000,000 over 3 years
The Mark Foundation Endeavor Awards support collaborative research projects that bring together investigators with diverse areas of expertise to tackle challenges in the prevention, diagnosis, and treatment of cancer. These grants are awarded to teams of three or more investigators to generate and integrate data from diverse lines of research and transform those insights into advances for cancer patients that could not be achieved by individual efforts.
Eligibility: Institutions are limited to one or two submissions as a host institution.
- The first submission from a given institution may address any cancer type.
- Institutions will be allowed a second submission as a host institution only for a translational or clinical stage project that primarily focuses on one of the following four cancer types: upper GI, glioblastoma, triple-negative breast cancer, or pancreatic cancer.
- No more than two applications may be submitted by any one institution.
Please send expressions of interest to Anthony Enterante (aenteranteiii@tulane.edu) no later than Wednesday, July 23, 2025.
| | |
Request for Proposals - Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma
DEADLINE - JULY 24
Projects that will be considered for Pfizer support will focus on:
- Safety and efficacy of elranatamab in the context of real-world use
- Outpatient administration of elranatamab and alternative CRS/ICANS mitigation strategies
- Impact of prior treatments (BsAb, CAR-T, ADC) on elranatamab outcomes, and wash-out period between treatments
- Infection patterns, timing, types, and management strategies including Ig replacement therapy
- Identifying clinical and biological features of refractoriness, early- or late-response, relapse to elranatamab and establishing response biomarkers
If you're interested in applying, please contact Tony Enterante, Ed.D, MBA, senior development officer for corporate, foundation and research relations, at aenteranteiii@tulane.edu.
MORE INFORMATION
| | |
AACR-Hope Scarves Metastatic Breast Cancer Innovation and Discovery Grant
APPLICATION DEADLINE: JULY 24
GRANT AMOUNT: $50,000 OVER 1 YEAR
This grant mechanism aims to foster innovation and advance the translation of promising ideas in metastatic breast cancer research, including the exploration of potential therapeutic targets and biomarkers. Research projects may be basic, clinical, or translational in nature and must have direct applicability and relevance to metastatic breast cancer. Applications are invited from researchers currently studying metastatic breast cancer, as well as investigators with experience in other areas of cancer or biomedical research. Grant funds may be used for research expenses attributable to the project, which may include supplemental salary support, equipment, research/laboratory supplies, and other research expenses. Indirect costs are not allowed.
MORE INFORMATION
| |
AACR Immuno-Oncology Research Fellowships
APPLICATION DEADLINE: JULY 29
GRANT AMOUNT: $130,000 OVER
2 YEARS
These grants are intended to encourage and support postdoctoral or clinical research fellows working on a mentored immuno-oncology research project. The proposed work may be in basic, translational, clinical, or population sciences research and must have direct applicability and relevance to immuno-oncology.
MORE INFORMATION
| | |
New! Cost caps for all FY25 PCRP funding opportunities have been changed from direct costs to total costs (direct plus indirect costs).
Prostate Cancer Research Program (PCRP):
The maximum allowable funding for FY25 PCRP funding opportunities is summarized below:
- Clinical Consortium Award:
- Coordinating Center: $10.5M for total costs (direct plus indirect costs)
- Clinical Research Sites: $2.0M for total costs (direct plus indirect costs)
-
Idea Development Award:
- Established Investigators: $1.7M for total costs (direct plus indirect costs)
- New Investigators: $2.1M for total costs (direct plus indirect costs)
To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=665102
IMPORTANT: The updated program announcements have been posted to Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Updates to program announcements that were posted to the CDMRP website are pending and will be updated soon.
| | |
OPEN DEADLINE - EARLIEST SUBMISSION AUGUST 9
The NIH Director’s Pioneer Award supports individual scientists of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator’s research program or elsewhere. Applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research.
MORE INFORMATION
| |
Arizona State University and Science Prize for Transformational Impact
DEADLINE: AUGUST 15
AWARD AMOUNT: GRAND PRIZE - $30,000 + ESSAY PUBLISHED IN SCIENCE (ONLINE AND PRINT); RUNNER-UP - $10,000 + ESSAY PUBLISHED IN SCIENCE ONLINE
Arizona State University and Science have partnered to create the ASU–Science Prize for Transformational Impact, which recognizes transformational research that uses innovative methods and approaches to identify problems and develop solutions with impacts on policy and decision-making.
MORE INFORMATION
| |
Damon Runyon Fellowship Award - Request for Applications
DEADLINE: AUGUST 15
AWARD AMOUNT:
This four-year award provides $70,000, $72,000, $74,000, and $76,000 in stipend support for years one, two, three, and four, respectively. In addition, an annual $2,000 expense allowance is awarded to the laboratory in which the Fellow is working and can be used by the Fellow for their educational and scientific expenses. The Foundation also provides a Dependent Child Allowance of $1,000 per child per year. The award may not be used for institutional overhead or indirect costs.
Applicants must have completed one or more of the following degrees or its equivalent: MD, PhD, MD/PhD, DDS, DVM, DO.
MORE INFORMATION
| |
LLS Discovery Grant Program Now Accepting Letters of Intent
DEADLINE: AUGUST 19
The Leukemia & Lymphoma Society (LLS) is pleased to announce the 2025-2026 application cycle of the Discovery Grant Program (DGP). This mechanism is designed to encourage basic research, technological innovation, and informatics pipeline development.
A detailed description of the LLS Discovery Grant Program and application instructions are available on the LLS Research Portal HERE. All applications MUST be submitted online through the LLS Research Portal.
For additional questions regarding LLS research grant programs, eligibility, and application processes, please contact researchprograms@lls.org.
| | |
OPEN DEADLINE - EARLIEST SUBMISSION AUGUST 25
This Notice of Funding Opportunity (NOFO) encourages applications for support of resources that will provide access to state-of-the-art equipment, technologies, research tools, materials, organisms, software, and/or services to a substantial regional (multi-state) or national user base. Only those resources with technical capabilities that fall within the NIGMS-supported program areas are eligible for awards. The resources should already be established or may be formed through consolidation of existing local or regional facilities. The intent is to provide resource access to investigators without regard to the specific biomedical focus of their research, while not duplicating or replacing resources supported by sources such as other NIH Institutes and Centers (ICs) or host institutions. The resource is expected to be maintained or upgraded to current best practices, make its capabilities and availability known to the biomedical research community through a robust web presence and outreach activities, and provide user training and support. The NOFO does not support major new research and development efforts. Stand-alone data resources and databases are not eligible.
MORE INFORMATION
| | |
The Hairy Cell Leukemia (HCL2030) Program
Now Accepting Letters of Intent
DEADLINE: SEPTEMBER 3 - 3 PM
The Hairy Cell Leukemia Foundation (HCLF) and The Leukemia & Lymphoma Society (LLS) have joined forces to invest $5 to 7 million over approximately five (5) years in hairy cell leukemia (“HCL”) research, including the HCLF Patient Data Registry. This initiative is called The Hairy Cell Leukemia Foundation-Leukemia & Lymphoma Society HCL2030 Initiative (HCL2030).
There are two funding mechanisms under HCL2030 as follows:
Laboratory to Clinical Research Grants (LCRGs)
- Projects focused on translational research, including basic research if justified, that has relevance to therapeutic development
- Project led by a single Principal Investigator (PI) but may have one co-PI
- 3 years of support, with the third-year funding dependent on progress assessment at the end of year 2
- Cost not to exceed $250,000/yr ($750,000 total), including direct costs
- Indirect costs (institutional overhead) capped at 10% of the total grant award; our goal is to maximize funds directed to actual research
- Funds intended for flexible use may include salaries (capped at 40%), equipment, supplies, or personnel.
- A Patient Involvement Plan (PIP) is required for LCRGs if a clinical trial is involved
Collaborative Team Grants (CTGs)
- Projects focused on the development and implementation of novel clinical trials that are feasible within the time period of the grant
- Program activities can include pre-clinical development and correlative studies
- Either one trial with supporting correlative work or multiple projects with related but distinct approaches that contribute to a transformational advance in the treatment of HCL
- Up to 4 investigators (Project Leaders) led by a Program Director (PD)
- Funding for core facilities (e.g., chemistry, genomics, animal models, computation) may be included but cannot exceed 20% of the total cost
- Up to 4 years of support
- Cost not to exceed $625,000/yr ($2,500,000 total), including indirect costs; more focused applications may not require the maximum amount of funding
- Indirect costs (institutional overhead) capped at 10% of the total grant award; our goal is to maximize funds directed to actual research
- Funds intended for flexible use may include salaries (capped at 40%), equipment, supplies, or personnel
- Demonstration of other financial support for the proposed work from industry or other NFPs, which leverages funding provided by HCLF and LLS is encouraged
- A Patient Involvement Plan (PIP) is required for CTG grants
A detailed description of the LLS Hairy Cell Leukemia (HCL2030) Program and application instructions are available on the LLS Research Portal or https://www.lls.org/research/apply-hairy-cell-leukemia. All applications are to be submitted online through the LLS Research Portal.
For additional questions regarding LLS research grant programs, eligibility, and application processes, please contact researchprograms@lls.org.
| |
NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
APPLICATION DEADLINE: SEPTEMBER 3
The NIH Director’s Transformative Research Award supports individual scientists or groups of scientists proposing bold, groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Applications in all topics relevant to the broad mission of NIH are encouraged, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH.
MORE INFORMATION
| | |
New! Cost caps for all FY25 MRP funding opportunities have been changed from direct costs to total costs (direct plus indirect costs).
Melanoma Research Program (MRP):
The maximum allowable funding for FY25 MRP funding opportunities is summarized below:
-
Focused Program Award – Rare Melanomas: $2.8M total costs (direct plus indirect costs)
-
Idea Award: $560,000 total costs (direct plus indirect costs)
-
Melanoma Academy Leadership Award: $1.82M total costs (direct plus indirect costs)
-
Melanoma Academy Scholar Award: $770,000 total costs (direct plus indirect costs)
-
Survivorship Research Award: $1.015M total costs (direct plus indirect costs)
-
Team Science Award: $2.1M total costs (direct plus indirect costs)
To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671103
IMPORTANT: The updated program announcements have been posted to Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Updates to program announcements that were posted to the CDMRP website are pending and will be updated soon.
| | |
New! Cost caps for all FY25 BCRP funding opportunities have been changed from direct costs to total costs (direct plus indirect costs).
Breast Cancer Research Program (BCRP):
The maximum allowable funding for FY25 BCRP funding opportunities is summarized below:
-
Breakthrough Award Levels 1 and 2 (BTA12):
- Funding Level 1: $750,000 (single PI) and $1.25M (Partnering PI Option) for total costs (direct plus indirect costs)
- Funding Level 2: $1.65M (single PI) and $2.5M (Partnering PI Option) for total costs (direct plus indirect costs)
- Funding Level 2 – Population Science and Prevention Studies: $2.5M (single PI) and $3.35M (Partnering PI Option) for total costs (direct plus indirect costs)
-
Breakthrough Award Level 3: $5.6M (single PI) and $7M (Partnering PI Option) for total costs (direct plus indirect costs)
-
Clinical Research Extension Award: $7M (single PI) and $8.4M (Partnering PI Option) for total costs (direct plus indirect costs)
-
Era of Hope Scholar Award: $4.9M for total costs (direct plus indirect costs).
To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=663101
IMPORTANT: The updated program announcements have been posted to Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Updates to program announcements that were posted to the CDMRP website are pending and will be updated soon.
| |
RFPs for Board of Regents Support Fund FY 2025-26 Competition
MANDATORY NOTICE OF INTENT DEADLINE - SEPTEMBER 11
PROPOSAL DEADLINE - OCTOBER 17
A request for proposals for FY 2025-26 is now available on the Research and Sponsored Initiatives website for the Board of Regents Support Fund (BoRSF)
Research Competitiveness Subprogram (RCS) and is outlined HERE.
The BoRSF seeks projects that, if funded, are likely to have clearly defined, significant benefits for Louisiana higher education and economic development. It is critical that applicants carefully read the RFP in its entirety to understand the requirements.
RCS has been substantially revised based on the current circumstances. Please note the following:
- Only one-year awards are available.
- The one-year funding limit is $200,000.
- Eligibility has been expanded to include any faculty applicant at an eligible institution who is facing barriers to competitiveness for federal or other external funding.
- The requirement of institutional matching for equipment purchases has been removed.
Programs that are not available for FY 2025-26:
Departmental Enhancement
R&D: Industrial Ties Research Subprogram (ITRS) with Proof-of-Concept/Prototype Initiative (PoC/P)
Awards to LA Artists and Scholars (ATLAS)
BoR/SREB Doctoral Support to Promote Student and Faculty Diversity
| | |
New! Cost caps for all FY25 MRP funding opportunities have been changed from direct costs to total costs (direct plus indirect costs).
Melanoma Research Program (MRP):
The maximum allowable funding for FY25 MRP funding opportunities is summarized below:
-
Focused Program Award – Rare Melanomas: $2.8M total costs (direct plus indirect costs)
-
Idea Award: $560,000 total costs (direct plus indirect costs)
-
Melanoma Academy Leadership Award: $1.82M total costs (direct plus indirect costs)
-
Melanoma Academy Scholar Award: $770,000 total costs (direct plus indirect costs)
-
Survivorship Research Award: $1.015M total costs (direct plus indirect costs)
-
Team Science Award: $2.1M total costs (direct plus indirect costs)
To view the program announcements and submit a pre-application, visit: https://ebrap.org/eBRAP/public/ProgramFY.htm?programFYId=671103
IMPORTANT: The updated program announcements have been posted to Grants.gov and the electronic Biomedical Research Application Portal (eBRAP). Updates to program announcements that were posted to the CDMRP website are pending and will be updated soon.
| | |
TNPRC Core and Research Services Seminar Series:
Flow Cytometry Core & Immunology Assay Services
TUESDAY, JULY 15 - 11:00 AM - NOON
TULANE NATIONAL PRIMATE RESEARCH CENTER AUDITORIUM (COVINGTON)
ZOOM LINK
This is the first installment in a new seminar series that will highlight Tulane National Primate Research Center's research cores and services. These seminars are an opportunity to learn about specialized equipment, expert teams, and unique capabilities that are available to support cutting-edge research.
| | |
Maximizing Collaboration with Microsoft Teams at Tulane
Tuesday, July 15 - 1:00 – 1:45 pm
This session will provide a behind-the-scenes look at how Teams can support project planning, document sharing, and productivity; Teams is so much more than just instant messaging and virtual meetings. Whether you're a Teams rookie or looking to get new ideas, you'll walk away with practical insights and examples for your team.
REGISTER
| | |
Call for Abstracts - Trainee Poster Competition at the 2025 Louisiana Obesity Conference
DEADLINE - TUESDAY, JULY 15 - 11:59 PM
The two-day event, scheduled for August 8-9, offers medical students, residents, and fellows a valuable opportunity to present case reports, case series, and research in bariatric and obesity medicine. Poster abstracts from medical students, residents, and fellows on bariatric and obesity medicine topics presented as case reports, case series, and research projects are welcomed.
| |
AACR Special Conference in Cancer Research: Advances in Pancreatic Cancer Research – Emerging Science Driving Transformative Solutions
ABSTRACT SUBMISSION DEADLINE: JULY 15
This meeting is the premier scientific forum focused solely on pancreatic cancer—from early detection to resistance mechanisms, as well as from tumor metabolism to next-generation immunotherapy and targeted strategies like KRAS inhibition.
If your research is pushing boundaries in the lab or reshaping care at the bedside, don’t miss this opportunity to share it on a global stage. Selected abstracts may be chosen for oral presentation alongside global leaders in the field.
Scholar-in-Training Awards are available for early-career investigators.
This conference takes place September 28-October 1 at Westin Copley Place in Boston, MA.
MORE INFORMATION
| | |
IP and Innovation Workshop Series
WEDNESDAY, JULY 16 - Noon - 2:00 PM
REYNOLDS BOARD ROOM, TIDEWATER BUILDING - 24TH FLOOR
Join the Office of Intellectual Property Management and the Tulane University Innovation Institute for an accessible intellectual property (IP) education workshop series, emphasizing practical knowledge, interactive learning, and meaningful engagement. Complimentary beverages and desserts will be provided at this interactive "lunch and learn" experience. Open to faculty, postdoctoral fellows, research staff, and senior graduate students from all Tulane campuses and schools.
REGISTER
| | |
AI Tools & Resources to Power Your Tech Toolkit
Thursday, July 17 - 10:00 – 10:45 am
This session will focus on AI-driven tools and resources that support all program topics—including Excel, Teams, Adobe, and Qualtrics—hosted and delivered via LinkedIn Learning. Participants will learn practical solutions to streamline workflows, automate tasks, and integrate platforms.
REGISTER
| | |
The SBIR/STTR
Advantage Series
JULY 22 - SEPTEMBER 23
Join the Louisiana Technology Transfer Office (LTTO) for a multi-part series designed to assist innovators, startups, and small businesses in navigating the SBIR/STTR process—from developing a competitive proposal to progressing through Phase II and preparing for commercialization.
REGISTER
| | |
Reporting Requirements for Non-U.S. Gifts and Contracts
DEADLINE: JULY 24, 2025
Tulane is required by law to track certain non-U.S. source gifts and contracts. To help with these reporting requirements, Tulane has created a Frevvo web form to collect and compile the numbers and information needed for proper reporting.
Access the Foreign Gift and Contract Reporting form
You are required to enter the information into the form for all gifts and contracts received by Tulane from foreign sources with an individual or aggregate value of more than $50,000 within the last six months (from January 1, 2025, through June 30, 2025).
Reportable gifts and contracts include any contract, gift, grant, endowment, award, scholarship, or donation of money or property of any kind, or any combination thereof, including a conditional or unconditional pledge of a contract, gift, grant, endowment, award, scholarship, or donation with a non-U.S. person, company, or government entity.
Please contact Christopher Dressler at cdressler1@tulane.edu or (504) 988-7919 if you have questions regarding this data request.
| |
SUCRE Summer Research Fellows Poster Symposia
The Louisiana Cancer Research Center (LCRC) Summer Undergraduate Cancer Research Experience (SUCRE) Fellows will present their summer projects in two poster symposia:
LCRC SUCRE Fellows Poster Symposium
Thursday, July 24, Noon - 1:00 PM
Louisiana Cancer Research Center, 1st Floor Conference Room
1700 Tulane Ave., New Orleans 70112
22nd Annual High School & Undergraduate Symposium
Friday, July 25
1:00 - 2:00 PM Presentations
2:30 - 3:00 PM Judging
3:00 - 3:30 PM Closing Ceremony
Lion's Eye Building, 1st Floor, Room 130
2020 Gravier St., New Orleans 70112
Both symposia are open to the public.
| | |
American Society of Hematology (ASH) Annual Meeting
December 6 - 9, 2025 -
Orlando, FL
ABSTRACT SUBMISSION DEADLINE: AUGUST 5
MORE INFORMATION
| | | |
Louisiana Obesity Conference
August 8 - 9, 2025
Loews New Orleans Hotel
| | Career Connections - Open Positions @ TCC | |
Hutchinson Bldg. Biosafety Cabinet Certifications
Next week, Biosafety Office technicians with support from Allometrics will be onsite at the Hutchinson Building to complete annual biosafety cabinet certifications. As part of the Office of Biosafety’s maintenance program, all biosafety cabinets in use are required to be certified annually. Please share with your laboratory personnel to prepare for this visit. Contact Hayley Callison at 985.871.4848 or hcallison@tulane.edu with any questions.
| | Connect with Us on Social Media | |
Please visit Tulane Cancer Center on Facebook, Instagram and LinkedIn and follow us for all the latest news in cancer research, education and patient care.
You can access our profile pages by clicking on the icons below.
| |
Access Funding Opportunities with Tulane’s PIVOT Subscription
Tulane provides all researchers access to PIVOT, a funding database that helps identify grant opportunities tailored to your research. This subscription-based resource is available through Sponsored Projects and is designed to streamline the funding search process.
All Tulane researchers already have profiles in PIVOT, making it easy to log in and start exploring.
By using PIVOT, you can:
- Search for funding opportunities from federal agencies, foundations, and private sponsors
- Set up personalized alerts to track relevant grants and deadlines
- Identify potential collaborators within Tulane and beyond
How to Access PIVOT
-
Go to Pivot: https://pivot.proquest.com/dashboard
- Click “Log In” and select “Use Institutional Login”
- Search for Tulane University and sign in with your Tulane credentials
- Review and update your profile to reflect your research interests
- Start searching for funding opportunities that match your work
If you haven’t logged in yet, we encourage you to do so and take advantage of this resource.
| |
Check out the SOM's New Calendar of Events HERE!
| | |
Tulane Cancer Center now has an institutional subscription to The Cancer Letter, an independent weekly newsletter that is the leading source of information on:
- National Cancer Institute
- cancer research funding
- cancer legislation and policy
- the pharmaceutical industry
Our institutional subscription allows anyone with a Tulane IP address to be automatically logged in when visiting www.cancerletter.com. For more information, please click here.
| |
Acknowledging Tulane Cancer Center Support in Publications
We suggest using the following wording when acknowledging Tulane Cancer Center support: "This work was supported by the Tulane Cancer Center, part of Tulane School of Medicine, and a consortium partner of the Louisiana Cancer Research Center."
One of the responsibilities of membership in the Tulane Cancer Center is acknowledgement of Cancer Center membership and/or use of shared resources, salary support or other Tulane Cancer Center funding in presentations and publications.
| |
Tulane Cancer Center Cores
The Tulane Cancer Center NGS Analysis Core team assists investigators with furthering their research through comprehensive processing and analysis of data obtained from widely used high-throughput sequencing applications.
More Information
| |
Cell Analysis Core
The Cell Analysis Core Facility is designed to collaborate with investigators and contribute to all aspects of the research process, including consultation in experimental design, data analysis and storage, troubleshooting, interpretation of results, and the preparation and production of presentation graphics.
More Information
| |
Organoid Core
The long-term goal of the Tulane Cancer Center Organoid Core is to generate novel pre-clinical models of breast, lung, and pancreatic cancer as translational platforms for investigators to advance their research. Currently, the Core is focused on assisting investigators who have already created their own pre-clinical models, or who require assistance using organoid models obtained through other sources to characterize their samples. The Core is available to assist with 2-D high-throughput screening and 3-D organoid screening by live-cell imaging (Incucyte SX5). In collaboration with Dr. Tiffany Seagroves, bio-imaging of pre-clinical, immunocompromised animal models is offered using the IVIS Lumina III (Revvity) instrument.
MORE INFORMATION
| |
Tulane Cancer Center Membership
Any Tulane University faculty member whose research relates to or could potentially relate to cancer – directly or indirectly – should become a member of the Tulane Cancer Center (TCC). As a member, you have access to TCC's funding opportunities, research collaboration events, and shared resources. Please click here for our membership guidelines and our online application form.
| | |
Trainee Membership in the Tulane Cancer Center
Tulane graduate students, medical students, postdocs, medical school-affiliated residents or fellows, and some undergraduates who are engaged in cancer-focused research can now apply to become Trainee Members of the Tulane Cancer Center.
Trainee Member applicants must be sponsored by a current Tulane Cancer Center Member and, once their membership is approved, will benefit through association with Tulane Cancer Center Research Programs and Disease-Oriented Teams, as well as access to shared resources for cancer-focused projects and invitations to scientific retreats, seminars and special events.
Please share this opportunity with your lab teams and other trainees/mentees.
To access the Trainee Membership Sponsor Nomination Form as well as the online membership application, please click here.
| |
Subscribe to Nexus
If you know someone who is interested in subscribing to Nexus, a weekly round-up of news and information for Tulane cancer researchers, please have them contact Melanie Cross at mcross@tulane.edu.
| | Send Us Your News / Share Your Feedback | |
Please share your feedback. Is this newsletter helpful? What other information should we include? And send us your news and announcements regarding seminars, workshops, funding opportunities, new grants, recent publications or events by emailing Melanie Cross at mcross@tulane.edu.
| | | | |
